- Amgen Inc AMGN and Neumora Therapeutics Inc have announced a strategic collaboration to advance neuroscience discovery, development, and commercialization.
- The companies will collaborate on programs by applying Neumora's proprietary precision neuroscience platform to insights generated by Amgen's deCODE genetics and human data research capabilities.
- Deal terms for the collaboration were not disclosed.
- In addition, Neumora has received a $100 million equity investment from Amgen and acquired exclusive global rights to Amgen programs targeting casein kinase 1 delta and glucocerebrosidase for neurodegenerative diseases.
- Related: Amgen's Lumakras Combo Therapy Shows Improved Response Rate In Colorectal Cancer.
- Price Action: AMGN stock closed 0.89% lower at $209.98 on Wednesday.
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
